S_mmary The aim of this study was to investigate the effect of the cyclo-oxygenase inhibitor ibuprofen on the acute-phase protein response and resting energy expenditure (REE) of weight-losing patients with pancreatic cancer. Patients with irresectable pancreatic cancer (n = 16) were treated with either ibuprofen (1200 mg day-' for 7 days (n = 10) or placebo (n = 6). A group of 17 age-related non-cancer subjects were also studied. Indirect calorimetry, anthropometry, multifrequency bioelectrical impedence analysis and serum C-reactive protein (CRP) estimation were performed immediately before and after treatment. Before treatment, total REE was significantly elevated in the pancreatic cancer patients compared with healthy controls (1499 ± 71 vs 1377 ± 58 kcal) (P<0.02). Following treatment the mean REE of the ibuprofen group fell significantly (1386 ± 89 kcal) compared with pretreatment values (1468 ± 99 kcal) (P<0.02), whereas no change was observed in the placebo group. Serum CRP concentration was also reduced in the ibuprofentreated group (pre-ibuprofen, 51 mg l'; post-ibuprofen, 29mgI '; P<0.05). These results suggest that ibuprofen may have a role in abrogating the catabolic processes which contribute to weight loss in patients with pancreatic cancer.
cancer cachexia syndrome is complex and involves features such as anorexia and asethenia, early satiety and hypercatabolism (Fearon, 1992) . Although anorexia and malabsorption are important factors contributing to the weight loss observed in patients with pancreatic cancer, the degree of wasting cannot be explained simply by a reduction in nutritional intake. It has been demonstrated that patients with pancreatic cancer have significantly elevated resting energy expenditure and that the most hypermetabolic are those with an ongoing hepatic acutephase protein response (APPR). The APPR is thought to be mediated by proinfammatory cytokines such as tumour necrosis factor (TNF) and interleukin 6 (IL-6) (Heinrich, 1990 ), which in turn have been shown to be capable of mediating a syndrome similar to cancer cachexia in animals (Tracey et Strassmann et al., 1993) . Furthermore, infusion of TNF has been shown to increase energy expenditure in man (Starnes et al., 1988) .
The mediators of the APPR in cancer and their role in producing the variety of metabolic changes associated with cachexia remain unclear. Interleukin 6, interleukin Ip and tumour necrosis factor alpha have all been implicated as potential mediators of the APPR through both direct and prostaglandin-mediated pathways (Heinrich, 1990) . Prostaglandins are thought to have an important role in regulating the inflammatory response. We propose that the prostaglandin-cytokine axis might be a potential target for therapeutic intervention in patients with cancer cachexia and that inhibiting the inflammatory response might result in reductions in both the hepatic acute-phase response and energy expenditure. Ibuprofen is a non-steroidal anti-inflammatory agent and a potent cyclo-oxygenase enzyme inhibitor which is known to inhibit some of the end-organ effects of the proinflammatory cytokines. In particular, ibuprofen has been shown to reduce body temperature and the metabolic rate of patients with burn injury (Wallace et al., 1992) and to reduce the level of the acute-phase response in some patients with rheumatoid arthritis (Cash et al., 1990) . This study investigates the effect of treatment with ibuprofen or placebo on energy expenditure and acute-phase protein production in patients with pancreatic cancer.
Materik and mthods
Patients A consecutive series of 16 patients with histologically proven adenocarcinoma of the pancreas with evidence of weight loss were entered into the study. None of the patients had undergone surgery in the preceding 2 months. All patients were judged on the basis of clinical evaluation to be free from metabolic or endocrine disorders. None of the patients was jaundiced, pyrexial or had clinical or radiological evidence of infection, or was severely anaemic. In addition, none of the study patients had a history of recent non-steroidal antiinflammatory drug usage or was taking steroid drugs. All patients had adequate pain control at the time of study. Ten paitents were allocated treatment with ibuprofen, and values for REE and CRP were compared before and after treatment. To exclude the possibility that either disease progression or familiarity with the method of indirect calorimetry could account for the observed reductions in REE, six patients with pancreatic cancer were given a placebo and measurements of REE and CRP performed before and after treatment. Patients receiving ibuprofen therapy took 1200 mg each day in three divided doses for 7 days. The six patients received one placebo tablet three times each day for 7 days. Resting energy expenditure Resting energy expenditure was measured by indirect calorimetry using a ventilated hood system (Deltatrac; S&W Vcwkers, UK). All recordings were conducted in a thermoneutral environment between 08.00 and 09.00 hours following an overnight fast with the patient lying supine and at rest. Before measurement the equipment was calibrated using gas containing 95% oxygen and 5% carbon dioxide at a known barometric pressure. Flow through the canopy was kept constant at 44.31 min-'. Gas analysis was performed using a paramagnetic oxygen analyser and an infra-red carbon dioxide analyser. Vo2 and Vc02 were measured over a 201mm period and processed on-line by a microprocessor and converted to mean energy expenditure using the abbreviated de Weir formula (de Weir, 1949) . This system provides measurements of Vo2 and Vco2 which have an error of less than 4% (Makita et al., 1990 There was no significant difference between the would be to remove the tumour and allow spontaneous *eated and placebo-treated cancer patients with recovery of nutritional status (Calman. 1982 (Reeds et al.. 1994) . This means that a proportion of amino acids mobilised from skeletal muscle will be oxidised. and the transfer of amino acids from one tissue to another will lead to a net loss of nitrogen from the body.
Whether the observed attenuation of the acute-phase response induced by ibuprofen (Figure 1 ) might improve significantly the overall nitrogen economy of the wasted cancer patient will require further long-term studies.
Ibuprofen is a non-steroidal anti-inflammatory drug with potent inhibitory action on the enzyme cyclo-oxygenase. It is known to inhibit some of the end-organ effects of the proinflammatory cytokines IL-6. IL-1 and TNF (Dinarello and Wolff. 1982: Durum et al.. 1985) . It (Fearon and Carter. 1988; Fearon et al., 1991 (Kunkel et al., 1986; West et al., 1993 
